Israeli firms develop high-speed 3D
printer for stem cells
Send a link to a friend
[May 25, 2016]
JERUSALEM (Reuters) - Israeli 3D
printer firm Nano Dimension has successfully lab-tested a 3D bioprinter
for stem cells, paving the way for the potential printing of large
tissues and organs, the company said on Wednesday.
|
While 3D printers are used already to create stem cells for
research, Nano Dimension said the trial, conducted with Israeli
biotech firm Accellta Ltd, showed its adapted printer could make
large volumes of high resolution cells quickly.
"3D bioprinting enabled by the two companies' technologies, means
that Nano Dimension and Accellta have the potential to accelerate
high fidelity and high viability manufacturing of living cellular
products," the companies said.
"Accellta's technology can deliver large quantities of high quality
cells which can be an enabler for printing even large and complex
tissues and organs," they said.

Trading in Nano Dimension shares was halted in Tel Aviv, pending the
publication of a significant announcement.
Market research firm IDTechEx forecasts the market for bioprinting
will grow rapidly over the next decade to as much as $6 billion in
2024 from $481 million in 2014.
According to IDTechEX, the technology has value for pre-clinical
drug discovery and testing, cosmetics safety testing, toxicology
assays, tissue printing and "organs on chips".
[to top of second column] |

By combining Nano Dimension's high speed ink jet capabilities with
Accellta's stem cell suspension technologies, Nano Dimension Chief
Executive Officer Amit Dror said they could "enable 3D printing at
high resolution and high volumes".
The companies said they would consider forming a new entity but did
not intend to invest significant capital directly to expand this
activity as they would raise funds separately for the use of the
joint entity.
(Reporting by Steven Scheer; editing by David Clarke)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |